| # | Drug | Count |
|---|---|---|
| 0 | LAMIVUDINE | 419 |
| 1 | LAMIVUDINE ORAL | 392 |
| 2 | RILPIVIRINE | 223 |
| 3 | RALTEGRAVIR | 214 |
| 4 | CABOTEGRAVIR AND RILPIVIRINE | 197 |
| 5 | TENOFOVIR DISOPROXIL FUMARATE | 195 |
| 6 | RITONAVIR | 187 |
| 7 | CABOTEGRAVIR | 161 |
| 8 | EMTRICITABINE | 153 |
| 9 | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | 150 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EQUISETUM ARVENSE TOP | 4 | 0.1538 |
| 1 | KAOLIN | 3 | 0.0545 |
| 2 | RALTEGRAVIR | 214 | 0.0408 |
| 3 | DORAVIRINE | 28 | 0.0355 |
| 4 | EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | 1 | 0.0333 |
| 5 | RILPIVIRINE | 223 | 0.0312 |
| 6 | CABOTEGRAVIR AND RILPIVIRINE | 197 | 0.0301 |
| 7 | CABOTEGRAVIR SODIUM | 48 | 0.0299 |
| 8 | ZINGIBER OFFICINALE | 2 | 0.0230 |
| 9 | DOLUTEGRAVIR SODIUM AND LAMIVUDINE | 82 | 0.0228 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD4-directed Blocking Antibody [EPC] | 8 | 0.0148 |
| 1 | CCR5 Co-receptor Antagonist [EPC] | 27 | 0.0118 |
| 2 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 575 | 0.0117 |
| 3 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 228 | 0.0095 |
| 4 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 946 | 0.0086 |
| 5 | Protease Inhibitor [EPC] | 243 | 0.0055 |
| 6 | Cytochrome P450 3A Inhibitor [EPC] | 311 | 0.0051 |
| 7 | Dihydrofolate Reductase Inhibitor Antimalarial [EPC] | 5 | 0.0039 |
| 8 | Rifamycin Antimycobacterial [EPC] | 9 | 0.0026 |
| 9 | Nucleoside Analog Antifungal [EPC] | 3 | 0.0021 |